Frontlight ResearchEarly access
Taking people in SpainPhase 4
Intravenous iron and quality of life in older adults after acute coronary syndrome
Tests intravenous iron in older adults with iron deficiency after acute coronary syndrome.
Key facts
- Who runs it
- Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
- Where
- Badajoz, Barcelona, Granada, León, Madrid, Murcia, Pamplona, Valencia, and Vigo, SpainSee the 9 sites
- Trial code
- Registry title
- Effect of intravenous iron on quality of life in older adults with acute coronary syndrome: a phase IV clinical study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 538 people, planned
- Started
- 27 Feb 2026
- Expected to end
- 28 Jan 2028
- Type of study
- Interventional
- Record updated
- 3 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 or older who had an acute coronary syndrome in the last 15 days and have iron deficiency that has not been treated.
- Age
- 65 years or older
- Sex
- All sexes can join.
- Disease stage
- Confirmed acute coronary syndrome within a maximum of 15 days before joining.
- Earlier treatment
- The iron deficiency must be untreated. People treated with intravenous or oral iron in the year before the event cannot join.
- Biomarker or test result
- Iron deficiency shown by serum ferritin <100 ng/mL or transferrin saturation (TSAT) <20%, found at hospital admission or within 15 days after the cardiac event.
Main reasons for not taking part
- Active cancer or ongoing bacteremia
- Heart failure with LVEF <40%
- Dialysis, or advanced liver or kidney failure
- Severe anemia (hemoglobin <10 g/dL)
- Known hypersensitivity to intravenous iron or its excipients
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients aged 65 years or older
- Patients with a confirmed diagnosis of acute coronary syndrome (ACS) within a maximum of 15 days prior to inclusion
- Patients with a confirmed diagnosis of iron deficiency at the time of hospital admission or within 15 days after the cardiac event, untreated, and defined by: - Serum ferritin <100 ng/mL, or - Transferrin saturation (TSAT) <20%, according to the European Society of Cardiology guidelines and the SEC_SEMI consensus
- Ability to understand the study details and to provide written informed consent prior to any trial-related procedures
Who cannot take part
- Patients with previously diagnosed iron deficiency, identified and treated with intravenous or oral iron within the year prior to the event
- Patients with active cancer
- Patients undergoing dialysis, or with advanced hepatic or renal failure
- Patients with known hypersensitivity to intravenous iron or to any of the excipients in the product
- Patients with known severe hypersensitivity to other parenteral iron products
- Evidence of iron overload or disorders in iron utilization
- Patients with a prior diagnosis of heart failure (HF) with a left ventricular ejection fraction (LVEF) <40%, or who develop this condition during hospitalization or within 15 days following the acute coronary syndrome (ACS) event will be excluded
- Patients with severe anemia (hemoglobin <10 g/dL) at the time of the event or within the subsequent 15 days
- Patients with ongoing bacteremia
- Patients currently participating in other clinical trials involving investigational medicinal products
- Patients who, in the opinion of the investigator, should not participate in the study due to difficulties in complying with procedures, restrictions, or requirements
- Terminally ill patients as determined by the IDC-Pal score (Instrument for Diagnosing Complexity in Palliative Care)
Where in Spain
- Hospital Universitario de BadajozBadajoz, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital Universitario Clínico San CecilioGranada, SpainTaking people
- Hospital Universitario De LeonLeón, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
- Hospital Alvaro CunqueiroVigo, SpainTaking people
About the trial
What the trial wants to find out
To determine whether patients aged 65 years or older, diagnosed with iron deficiency after an acute coronary syndrome (ACS), who receive intravenous iron treatment have a better quality of life at 6 and 12 months of follow-up compared to patients who do not receive treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase IV, open-label, randomized clinical trial on the effect of intravenous iron on quality of life in elderly patients with Acute Coronary Syndrome.
- Plain-language title
- Intravenous iron and quality of life in older adults after acute coronary syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 December 2025